Apnimed, Inc. Common Stock (APMD) - Net Assets
Based on the latest financial reports, Apnimed, Inc. Common Stock (APMD) has net assets worth $257.59 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($342.63 Million) and total liabilities ($85.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Apnimed, Inc. Common Stock net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $257.59 Million |
| % of Total Assets | 75.18% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Apnimed, Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Apnimed, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore Apnimed, Inc. Common Stock (APMD) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Net Assets for Apnimed, Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Apnimed, Inc. Common Stock from 2024 to 2025. For live market cap and overall valuation, see market value of Apnimed, Inc. Common Stock.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-372.78 Million | -49.94% |
| 2024-12-31 | $-248.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Apnimed, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12819100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $24.56 Million | % |
| Total Equity | $-372.78 Million | 100.00% |
Apnimed, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Apnimed, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Senvest Capital Inc.
TO:SEC
|
$771.03 Million |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
$771.04 Million |
|
Ocean’s King Lighting Science & Technology Co Ltd
SHE:002724
|
$771.07 Million |
|
Shandong Ruifeng Chemical Co Ltd
SHE:300243
|
$771.13 Million |
|
Criteo Sa
NASDAQ:CRTO
|
$770.73 Million |
|
Diversified United Investment Ltd
AU:DUI
|
$770.60 Million |
|
Grupo Posadas S.A.B. de C.V
MX:POSADASA
|
$770.53 Million |
|
Tianjin Printronics Circuit Corp
SHE:002134
|
$770.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apnimed, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -248,615,000 to -372,783,000, a change of -124,168,000.
- Net loss of 932,000 reduced equity.
- New share issuances of 16,500,000 increased equity.
- Other factors decreased equity by 139,736,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-932.00K | -0.25% |
| Share Issuances | $16.50 Million | +4.43% |
| Other Changes | $-139.74 Million | -37.48% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Apnimed, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Apnimed, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.42%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | -1389.23% | 0.07x | 0.00x | $-86.44 Million |
| 2025 | 0.00% | -2.42% | 0.53x | 0.00x | $36.35 Million |
Industry Comparison
This section compares Apnimed, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $142,965,128
- Average return on equity (ROE) among peers: -89.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Apnimed, Inc. Common Stock (APMD) | $257.59 Million | 0.00% | 0.33x | $770.86 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $103.64 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $282.49 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $154.57 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $106.02 Million | -68.71% | 0.36x | $836.01 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $7.69 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $12.11 Million | -372.67% | 3.10x | $3.41 Billion |
About Apnimed, Inc. Common Stock
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambr… Read more